Loading…
Loading…
CARM does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for CARM and 80,000+ other tickers.
See exactly how CARM's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for CARM and 80,000+ other tickers.
Carisma Therapeutics, Inc., a biotechnology company, focuses on developing transformative therapies to treat liver fibrosis and cancer in the United States. Its product candidates include CT-2401, which is in preclinical trial for the treatment of liver fibrosis. The company also develops CT-1119, a mesothelin-targeted CAR-Monocyte that is in phase I clinical trial to treat patients with advanced mesothelin-positive solid tumors, including pancreatic cancer, ovarian cancer, lung cancer, mesothelioma, and others. In addition, it develops in vivo CAR-M cell therapy to treat solid tumors…
Carisma Therapeutics (NASDAQ: CARM - Get Free Report) and Protalex (OTCMKTS:PRTX - Get Free Report) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, profitability, valuation, analyst recommendations, dividends and institutional ownership. Insider and Institutional Ownership 44.3% of Carisma Therapeutics shares
PARIS--(BUSINESS WIRE)--Regulatory News: Carmila (Paris:CARM): Three growth engines: NRI up 8.8% to €403.1 million Organic growth: adding 3.5% to net rental income, outpacing indexation by 110 basis points. Investment growth: adding 5.3% to net rental income; successful integration of Galimmo Innovation growth: recurring earnings contribution of €27 million, growing by 14% Operational excellence confirmed, all KPIs on an upward trend High financial occupancy rate: up 30 basis points to 96.5% Re.
Context Therapeutics (NASDAQ: CNTX - Get Free Report) and Carisma Therapeutics (NASDAQ: CARM - Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, valuation, risk, institutional ownership, profitability and dividends. Insider and Institutional Ownership 14.0% of Context
PHILADELPHIA , Dec. 5, 2025 /PRNewswire/ -- Carisma Therapeutics Inc. (OTCID: CARM) (the "Company") today announced that its Board of Directors (the "Board") has approved and the Company intends to proceed with the voluntary delisting of its common stock from The Nasdaq Stock Market LLC ("Nasdaq") and the deregistration of its common stock in order to suspend and ultimately terminate the Company's reporting obligations under the Securities and Exchange Act of 1934, as amended (the "Exchange Act"). As previously reported, as a result of the Company's previously disclosed noncompliance with the bid price, market value of listed securities, and market value of publicly held shares requirements set forth in Nasdaq Listing Rules 5450(a)(1), 5450(b)(2)(C), and 5450(b)(2)(A), respectively, the Company received a delist determination letter from Nasdaq on October 9, 2025 (the "Determination Letter") and the Company's common stock was suspended from trading on Nasdaq effective at the open of business on October 13, 2025.
Carisma Therapeutics (NASDAQ: CARM - Get Free Report) and Achieve Life Sciences (NASDAQ: ACHV - Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, profitability, valuation, institutional ownership and risk. Analyst Recommendations This is a breakdown